---
title: "Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285188644.md"
description: "Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Axsome Therapeutics (AXSM) with a price target of $310.00. Suvannavejh, who focuses on the Healthcare sector, has an average return of 19.9% and a success rate of 48.98% on his stock recommendations. Additionally, H.C. Wainwright's Ram Selvaraju also issued a Buy rating for Axsome Therapeutics, while Morgan Stanley maintained a Hold rating on the stock."
datetime: "2026-05-05T10:38:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285188644.md)
  - [en](https://longbridge.com/en/news/285188644.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285188644.md)
---

# Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics today and set a price target of $310.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Suvannavejh covers the Healthcare sector, focusing on stocks such as Insmed, Verastem, and Immuneering. According to TipRanks, Suvannavejh has an average return of 19.9% and a 48.98% success rate on recommended stocks.

In addition to Mizuho Securities, Axsome Therapeutics also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued today. However, on the same day, Morgan Stanley maintained a Hold rating on Axsome Therapeutics (NASDAQ: AXSM).

### Related Stocks

- [AXSM.US](https://longbridge.com/en/quote/AXSM.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [VSTM.US](https://longbridge.com/en/quote/VSTM.US.md)
- [IMRX.US](https://longbridge.com/en/quote/IMRX.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions](https://longbridge.com/en/news/286077483.md)
- [Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch](https://longbridge.com/en/news/286164148.md)
- [Oppenheimer & Co. Inc. Takes $1.29 Million Position in Axsome Therapeutics, Inc. $AXSM](https://longbridge.com/en/news/285520861.md)
- [Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock](https://longbridge.com/en/news/285297559.md)
- [HB Wealth Management LLC Has $6.23 Million Position in Axsome Therapeutics, Inc. $AXSM](https://longbridge.com/en/news/283976583.md)